Toward a reduction of the global burden of cervical cancer

American Journal of Obstetrics and Gynecology

Volumn 189, Issue 4 SUPPL., 2003, Pages

  Rohan, Thomas E ^a   Burk, Robert D ^a   Franco, Eduardo L ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Cervical cancer; Human papilloma viruses; Prevention; Screening; Vaccination

Indexed keywords

ONCOPROTEIN; UNCLASSIFIED DRUG; VIRUS ONCOPROTEIN E6; VIRUS ONCOPROTEIN E7; VIRUS PROTEIN; VIRUS VACCINE; WART VIRUS VACCINE;

BODY BURDEN; CANCER SCREENING; CLINICAL TRIAL; DEVELOPING COUNTRY; DISEASE BURDEN; DRUG EFFECT; FEMALE; GENE GUN; GENE TARGETING; HUMAN; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS INFECTION; VIRUS PARTICLE; VIRUS PATHOGENESIS; WART VIRUS;

EID: 0242475322     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/S0002-9378(03)01079-2     Document Type: Article

References (21)

1. Pisani P, Parkin DM, Bray F, et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:870-3.
2. Holowaty P, Miller AB, Rohan T, et al. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999;91:252-8.
3. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64.
4. IARC Working Group. IARC Monographs on the evaluation of carcinogenic risks to humans: Human papillomaviruses. Vol. 64. Lyon, France: IARC; 1995.
5. Franco E, Ferenzy A: Cervical cancer: Epidemiology, risk factors, and role of human papillomavirus infection. Can Med Assoc J (in press).
6. Bosch EX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
7. Liaw KL, Glass AG, Manos MM, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999;91:954-60.
8. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
9. Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 1999;91:506-11.
10. Wallin KL, Wiklund F, Angstrom T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-8.
11. Heselmeyer K, Schrock E, du Manoir S, et al. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci USA 1996;93:479-84.
12. Kuhne C, Banks L. Cellular targets of the papillomavirus E6 proteins. Papillomavirus Report 1999;10:139-45.
13. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996;380:79-82.
14. Schiffman MH, Brinton LA, Devesa SS, et al. Cervical cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer Epidemiology and Prevention. 2nd ed. New York, NY: Oxford University Press; 1996. p. 1090-116.
15. Meheus A. Prevention of sexually transmitted infections through health education and counseling: A general framework. In: Franco EL, Monsonego J, editors. New Developments in Cervical Cancer Screening and Prevention. London, England: Blackwell; 1997. p. 84-90.
16. Schiller JT. Papillomavirus-like particle vaccines for cervical cancer. Mol Med Today 1999;5:209-15.
17. Balmelli C, Roden R, Potts A, et al. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 1998;72:8220-9.
18. Cuzick J, Sasieni P, Davies P, et al. A systematic review of the role of human papillomavirus testing within a cervix screening programme. Health Technol Assess 1999;3:1-204.
19. Hutchinson ML, Berger BM, Farber FL. Clinical and cost implications of new technologies for cervical cancer screening: The impact of test sensitivity. American Journal of Managed Care 2000;6:766-80.
20. Cuzick J. Human papillomavirus testing for primary cervical cancer screening. JAMA 2000;283:108-9.
21. Wright TC, Denny L, Kuhn L, et al. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81-6.